TY - JOUR
T1 - Raloxifene administration in post-menopausal women with osteoporosis
T2 - Effect of different BsmI vitamin D receptor genotypes
AU - Palomba, Stefano
AU - Numis, Fabio Giuliano
AU - Mossetti, Giuseppe
AU - Rendina, Domenico
AU - Vuotto, Pietro
AU - Russo, Tiziana
AU - Zullo, Fulvio
AU - Nappi, Carmine
AU - Nunziata, Vincenzo
PY - 2003/1/1
Y1 - 2003/1/1
N2 - Background: The vitamin D receptor (VDR) gene polymorphism has been considered a factor influencing the effectiveness of the anti-osteoporotic treatments. The aim of this study was to correlate the effectiveness of raloxifene treatment in post-menopausal women with osteoporosis to BsmI VDR genotypes. Methods: Between January and August 2000, 75 Italian osteoporotic women were enrolled and treated with raloxifene at a dose of 60 mg/day. At entry and after 1 year of treatment, lumbar bone mineral density (BMD), serum osteocalcin (OC) and urinary creatinine-corrected free deoxypyridinoline (DPD) levels were evaluated. DNA was extracted from blood and analysed with restriction endonuclease BsmI for VDR gene. Results: After treatment, a significant increase in lumbar BMD and a significant reduction in serum OC and urinary DPD levels were observed. The percentage of change (mean ± SD) in lumbar BMD, and in serum OC and urinary DPD levels was significantly different in homozygous bb (1.58 ± 0.80, -5.15 ± 2.36 and -7.71 ± 2.89 for BMD, OC and DPD respectively) in comparison with BB (4.13 ± 2.26, -13.59 ± 4.68 and -15.16 ± 4.65 for BMD, OC and DPD respectively) BsmI VDR genotypes. Heterozygous Bb VDR patients showed an intermediate percentage (mean ± SD) of BMD, serum OC and urinary DPD change (2.49 ± 1.54, -8.69 ± 2.60 and -10.52 ± 2.56 for BMD, OC and DPD respectively) not significantly different in comparison with homozygous BB and bb. Conclusions: In post-menopausal women with osteoporosis the effectiveness of raloxifene treatment on bone metabolism seems to be controlled by different BsmI VDR genotypes.
AB - Background: The vitamin D receptor (VDR) gene polymorphism has been considered a factor influencing the effectiveness of the anti-osteoporotic treatments. The aim of this study was to correlate the effectiveness of raloxifene treatment in post-menopausal women with osteoporosis to BsmI VDR genotypes. Methods: Between January and August 2000, 75 Italian osteoporotic women were enrolled and treated with raloxifene at a dose of 60 mg/day. At entry and after 1 year of treatment, lumbar bone mineral density (BMD), serum osteocalcin (OC) and urinary creatinine-corrected free deoxypyridinoline (DPD) levels were evaluated. DNA was extracted from blood and analysed with restriction endonuclease BsmI for VDR gene. Results: After treatment, a significant increase in lumbar BMD and a significant reduction in serum OC and urinary DPD levels were observed. The percentage of change (mean ± SD) in lumbar BMD, and in serum OC and urinary DPD levels was significantly different in homozygous bb (1.58 ± 0.80, -5.15 ± 2.36 and -7.71 ± 2.89 for BMD, OC and DPD respectively) in comparison with BB (4.13 ± 2.26, -13.59 ± 4.68 and -15.16 ± 4.65 for BMD, OC and DPD respectively) BsmI VDR genotypes. Heterozygous Bb VDR patients showed an intermediate percentage (mean ± SD) of BMD, serum OC and urinary DPD change (2.49 ± 1.54, -8.69 ± 2.60 and -10.52 ± 2.56 for BMD, OC and DPD respectively) not significantly different in comparison with homozygous BB and bb. Conclusions: In post-menopausal women with osteoporosis the effectiveness of raloxifene treatment on bone metabolism seems to be controlled by different BsmI VDR genotypes.
KW - Bone mineral density
KW - Osteoporosis
KW - Post-menopause
KW - Raloxifene
KW - Vitamin D receptor gene polymorphisms
UR - http://www.scopus.com/inward/record.url?scp=0037253341&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037253341&partnerID=8YFLogxK
U2 - 10.1093/humrep/deg031
DO - 10.1093/humrep/deg031
M3 - Article
C2 - 12525466
AN - SCOPUS:0037253341
VL - 18
SP - 192
EP - 198
JO - Human Reproduction
JF - Human Reproduction
SN - 0268-1161
IS - 1
ER -